Cosentyx unoready 300 MG pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQW0K
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $84,706
Award facts
- Contract value 100% obligated
- $84,706.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, issued on February 4, 2026, awards Amerisourcebergen Drug Corp (subsidiary of Cencora, Inc.) a firm fixed-price contract valued at $84,706.38 to supply Cosentyx (secukinumab) 300 mg pen auto-injectors in 2 ml formulations to the Defense Logistics Agency. The contract is scheduled for completion by February 5, 2026, with performance at the awardee's facility in Conshohocken, Pennsylvania. This award was made on a fully competitive, non-set-aside basis and represents a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a single-award vehicle valued at up to $999,999,999.00 through December 2026, which serves as the primary mechanism for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Cosentyx is a biologic immunosuppressant used to treat inflammatory conditions including psoriasis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases. DLA's procurement of this specialty medication through its Medical Supply Chain reflects ongoing support for military treatment facilities and veteran healthcare programs requiring access to contemporary biologic therapeutics. Amerisourcebergen's established position as a major federal pharmaceutical vendor, combined with its infrastructure as a critical distributor in the military healthcare supply chain, positions the company to efficiently fulfill this medical commodity requirement across the Defense Health Agency and associated federal medical institutions.
Quick answers
Who was awarded contract SPE2DR26FQW0K?
SPE2DR26FQW0K was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FQW0K worth?
The government has obligated $84,706 on SPE2DR26FQW0K.
Is contract SPE2DR26FQW0K an order under another contract?
Yes. SPE2DR26FQW0K is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQW0K competed?
The extent of competition for SPE2DR26FQW0K was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award